C61
Conditions
Interventions
Group 1: Biodistibution with 99mTc-BTG-N4
Sponsors
Klinik für Nuklearmedizin, Universitätsklinikum Augsburg
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically confirmed prostate carcinoma and an examination with 99mTc-BTG-N4
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the retrospective analysis is to determine the biodistribution of the GRPR ligand 99mTc-BTG-N4 and in particular the radiation dose for organs and the whole body. time period: 05.07.2021 - 20.07.2022 Method: The "Volume of Interest" is drawn around the corresponding organs and the activity concentration in the different acquired images is determined. Other clinical parameters and the activity values show the residence time of the radiopharmaceutical in the individual organs. | — |
Countries
Germany
Contacts
Public ContactLuisa Amann
Klinik für Nukelarmedizin
Outcome results
None listed